 |
SEOUL, South Korea, May 20, 2026 /PRNewswire/ — Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus.
Hyundai Bioscience said that if the World Health Organization (WHO) or countries affected by infectious disease outbreaks request support for XAFTY®, it can immediately provide products currently in stock.
According to the company, niclosamide, the main ingredient of XAFTY®, has previously been reported to have inhibitory effects against Ebola and hantavirus.
The company stated, “In the ongoing Phase 2 clinical trial of XAFTY® for dengue fever in Vietnam, no adverse events have been reported so far,” and claimed that “in a situation where two viruses are spreading simultaneously, XAFTY® could serve as an effective alternative.”
Hyundai Bioscience added that, as a member of the Medical CBRN Defense Consortium (MCDC), a U.S. Department of Defense-supported consortium, it will actively cooperate in responding to international public health crises.
CONTACT：
Jason Kim
[email protected]
(562) 964-3910
ข่าวที่เกี่ยวข้อง
- Hyundai Bioscience Discloses XAFTY®’s IC50 Data for Ebola–“Secured Scientific Evidence for Immediate Treatment”
- Singapore Court of Appeal Notes No Finding of Fraud Against KBP or Dr. Huang; Dispute with Novo Nordisk Undergoing Arbitration Proceedings
- Cohen & Steers Announces Strategic Partnership with J.P. Morgan to Expand Access to Short Duration Hybrid Credit SICAV Strategy
- GIGABYTE เปิดตัว AORUS MASTER 16 โน้ตบุ๊กเกมมิ่ง AI ระดับพรีเมียม พร้อมวางจำหน่ายแล้ววันนี้ ยกระดับทั้งพลังการประมวลผลอัจฉริยะและประสบการณ์การเล่นเกมที่สมจริง
